The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com

Alnylam Pharmaceuticals Stock Forecast

Recent Alnylam Pharmaceuticals Stock Price   Alnylam Pharmaceuticals Stock Forecast Price
$145.32 Alnylam Pharmaceuticals stock forecast: higher
+50.64%
$218.91
 As of 2024-04-18
Recent Alnylam Pharmaceuticals Analyst Ratings Breakdown
  Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong buy ratings: 13 13 13 14
Buy ratings: 3 3 3 3
Hold ratings: 9 9 9 7
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 1.84 1.84 1.84 1.71
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.

The presented Alnylam Pharmaceuticals stock forecast (traded under symbol ALNY), for forward-twelve-months price target as shown at the top of this page, gives you the average Alnylam Pharmaceuticals stock forecast for forward target price for symbol ALNY, across the 22 analysts covering Alnylam Pharmaceuticals (ALNY), as reported in data provided by Zacks Investment Research via Quandl.com.

Investors should also take note that the median Alnylam Pharmaceuticals stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Alnylam Pharmaceuticals stock forecast and half had a lower Alnylam Pharmaceuticals stock forecast) was $216.0 as of 2024-04-18 (which is a different mathematical metric versus taking the average or mean), while the highest Alnylam Pharmaceuticals stock forecast in the analyst group was $395.0, and the lowest Alnylam Pharmaceuticals stock forecast in the analyst group was $136.0, with a standard deviation of $53.969. Get the latest Zacks research report on ALNY — FREE

Slideshow Top Analyst Picks of the Dow
Slideshow The Top 20 Largest U.S. Stocks By Market Cap

Company Name:  Alnylam Pharmaceuticals Inc
Website:  www.alnylam.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ALNY:  58
Total Market Value Held by ETFs:  $2.06B
Total Market Capitalization:  $18.48B
% of Market Cap. Held by ETFs:  11.14%
April 19, 2024    2:01 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree ALNY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.16 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Alnylam Pharmaceuticals Stock Forecast (ALNY) | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.